Peter Rahal, Co-founder and CEO of RXBar, says the company was founded on the transparency of its ingredients, and that purpose led to a $600 million buyout from Kellogg. Rahal explains why ever ingredient in every product is in bold letters on the front of the package. When the company started out, "people would be like ‘well what is it?'” So they made the answer easy to find. Rahal discusses RXBAR's $600 million sale to Kellogg, and the future direction of the company, where he will remain as CEO. We talk about the whirlwind the company's evolution has been, given that it was founded in 2013, when Rahal and his co-founder were both broke. Then we look ahead to what's next for the company after the Kellogg buyout.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More